Reduced TET2 activity and 5-hydroxymethylcytosine (5hmC) levels were observed in AML, MDS, chronic myelomonocytic leukemia (CMML), lymphoid leukemia, and other patients with hematological malignancies. Here, TET2 is linked to hematologic disorder.